A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: RSUP4 /SUPand RSUP5 /SUPtogether are either -S-C(RSUP6/SUP-C(RSUP7/SUP)- or -C(RSUP7/SUP)-C(RSUP6/SUP)-S-; RSUP6 /SUPand RSUP7 /SUPare independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; RSUP1 /SUPis halo, cyano or carboxy; RSUP2 /SUPis for example methyl; RSUP3 /SUPis for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, tifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
展开▼
机译：式（1）的化合物或其药学上可接受的盐或前药; （1）其中，例如：R 4 和R 5 一起是-SC（R 6 -C（R 7 ）-或-C（R 7 ）-C（R 6 ）-S-; R 6 和R 7 独立地选自氢和卤素; A为亚苯基或杂亚芳基; n为0、1或2; R 1 为卤素，氰基或羧基; R 2 < / SUP>例如是甲基; R 3 例如选自卤素（1-4C）烷基，二卤（1-4C）烷基，三氟甲基，羟基（1-4C）烷基，二羟基（ 2-4C）烷基，三羟基（3-4C）烷基，氰基（1-4C）烷基（可选在烷基上被羟基取代），（1-4C）烷氧基（1-4C）烷基，（1-4C）烷氧基（ 1-4C）烷氧基（1-4C）烷基，二[（1-4C）烷氧基]（1-4C）烷基，（羟基）[（1-4C）烷氧基]（1-4C）烷基;具有糖原磷酸化酶抑制作用活性，因此在治疗与糖原磷酸化酶活性增加有关的疾病中具有价值，描述了化合物的制备方法和含有它们的药物组合物。
展开▼
